logo image
search icon
Vaccine Contract Manufacturing Market

Vaccine Contract Manufacturing Market Size, Share & Trends Analysis Report By Vaccine Type (Attenuated, Inactivated, Subunit-based, Toxoid-based, DNA-based), By Type of Expression System, By Workflow, By Application, By Region, And By Segment Forecasts, 2023-2031.

Report ID : 2303 | Published : 2024-01-23 | Pages: 179 | Format: PDF/EXCEL

Vaccine Contract Manufacturing Market Size is valued at USD 1.58 Bn in 2023 and is predicted to reach USD 5.79 Bn by the year 2031 at a 17.8% CAGR during the forecast period for 2024-2031.

Vaccine Contract Manufacturing Market

Vaccine contract manufacturing plays a vital role in the pharmaceutical industry, contributing to the efficient and scalable production of vaccines to address various health challenges worldwide. With the expanding efforts in global vaccine distribution, the ability to manage various facets of vaccine manufacturing and logistics positions Contract Manufacturing Organizations (CMOs) to play an important role in ensuring fair access to vaccines worldwide. Consequently, diversifying services becomes a strategic manoeuvre that not only enhances the market presence of CMOs but also contributes to addressing global health challenges. Additionally, advancements in vaccine technology, driven by innovations such as genetic engineering, vaccine delivery technology, and proteomics, continue to shape the industry's dynamic landscape. 

Moreover, the increasing implementation of strategic initiatives by key industry players, including activities such as business expansion, partnerships, and acquisitions, also reinforces the projected market growth. The rising global demand for vaccine contract manufacturing is set to propel market expansion.

Competitive Landscape

Some Major Key Players In The Vaccine Contract Manufacturing Market:

  • Lonza
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Ajinomoto Althea, Inc.
  • Merck KgaA
  • Cytovance Biologics
  • Catalent, Inc.
  • IDT Biologika GmbH
  • Albany Molecular Research, Inc.
  • PRA Health Sciences
  • ICON plc.
  • Pharmaceutical Product Development, LLC
  • Cobra Bio
  • Paragon Bioservices, Inc.
  • Charles River Laboratories
  • Meridian Life Science (MLS)
  • Eurogentec
  • GreenPak Biotech
  • Hong Kong Institute of Biotechnology
  • WuXi Biologics
  • Bharat Biotech
  • Biological E
  • Others

Market Segmentation

The global market of vaccine contract manufacturing is segmented on the basis of Vaccine Type, Type of Expression System, Workflow, and Application. The vaccine Type segment is categorised into Attenuated, Inactivated, Subunit-based, Toxoid-based, and DNA-based. By Type of Expression System, the market is segmented into Avian Expression Systems, Bacterial Expression Systems, Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs), Insect Expression Systems, Mammalian Expression Systems, Plant Expression Systems, and Yeast Expression Systems. The Workflow segment consists of Downstream and Upstream. As per the Application segment, the market is divided into Human Use and Veterinary.

The Segment Of Inactivated Vaccines Is Projected To Dominate The Market For Vaccine Contract Manufacturing During The Forecast Period.

Inactivated vaccinations consist of whole bacteria or viruses rendered non-viable or altered to prevent reproduction. Due to the absence of live bacteria or viruses, these vaccines are incapable of transmitting the diseases they are designed to protect against, even in individuals with severely weakened immune systems. This characteristic represents a significant benefit of this vaccine category.

Based On The Type Of Expression Systems, The Mammalian Segment Is A Major Contributor To The Vaccine Contract Manufacturing Market. 

The mammalian category is expected to hold a major share of the global Vaccine Contract Manufacturing market in 2022. The increasing prominence of mammalian cell culture technology has become a notable trend in the vaccine contract manufacturing market. Mammalian cell culture is gaining significance as a preferred method for vaccine production due to its ability to replicate complex biological systems and produce a wide range of proteins. This technology offers advantages such as enhanced yield, scalability, and the ability to produce more complex and effective vaccines. As a result, the rising utilization of mammalian cell culture in vaccine contract manufacturing is shaping the landscape of the market, contributing to its growth and innovation. This trend underscores the industry's ongoing efforts to improve vaccine manufacturing processes and meet the growing demand for safe and effective vaccines.

The Human-Use Segment Witnessed Growth At A Rapid Rate.

In recent years, the human-use category has dominated the market with the highest share. The extensive immunization coverage against various diseases in humans has resulted in this sector gaining the leading position in the market.

In The Region, The North America Vaccine Contract Manufacturing Market Holds A Significant Revenue Share.

The North America Vaccine Contract Manufacturing market is expected to register the highest market share. Advantages include a well-established biotechnology and pharmaceutical sectors, a sizable population, and a strong emphasis on healthcare that drives up vaccine demand. The area is a desirable location for contract manufacturing organizations (CMOs) due to its advanced manufacturing infrastructure, highly qualified labour, and well-established regulatory frameworks. Leading vaccine developers and government programs to support vaccine production reinforce North America's leading position in the market and establish it as a main driver of the sector's expansion. In addition, Asia Pacific is estimated to grow at a rapid rate in the global Vaccine Contract Manufacturing market.

The area gains from having highly qualified labourers and sophisticated manufacturing resources. Furthermore, it is a desirable location for vaccine contract manufacturing due to its favourable regulatory conditions and lower labour costs. Hence, Asia-Pacific continues to play a significant role in expanding the global vaccine contract manufacturing market. 

Recent Developments:

  • In Oct 2023, Vaxcyte, Inc. and Lonza have recently established a fresh commercial production arrangement. This partnership further facilitates the eventual worldwide commercialization of Vaxcyte's PCV candidates, VAX-24 and VAX-31, in both adults and children. This arrangement enhances Vaxcyte's strategy to leverage Lonza's existing infrastructure for the purpose of accelerating clinical development and facilitating the expected initial introduction of VAX-24 for the adult demographic in the United States.
  • In March 2021, Catalent has enhanced its collaboration with Johnson & Johnson to substantially augment the capability for sterile production and packaging of the COVID-19 vaccine in Italy. Catalent and Janssen had already reached an agreement to allocate an already existing vial-filling line at the Anagni factory.

Vaccine Contract Manufacturing Market Report Scope

Report Attribute

Specifications

Market Size Value In 2023

USD 1.58 Bn

Revenue Forecast In 2031

USD 5.79 Bn

Growth Rate CAGR

CAGR of 17.8 % from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Vaccine Type, By Type of Expression System, By Workflow, By Application

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea

Competitive Landscape

Lonza, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Ajinomoto Althea, Inc., Merck KgaA, Cytovance Biologics, Catalent, Inc., IDT Biologika GmbH, Albany Molecular Research, Inc., PRA Health Sciences, ICON plc., Pharmaceutical Product Development, LLC, Cobra Bio, Paragon Bioservices, Inc., Charles River Laboratories, Meridian Life Science (MLS), Eurogentec, GreenPak Biotech, Hong Kong Institute of Biotechnology, WuXi Biologics, Bharat Biotech, Biological E, Others

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Vaccine Contract Manufacturing Market Snapshot

Chapter 4. Global Vaccine Contract Manufacturing Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Industry Analysis – Porter’s Five Forces Analysis

4.6. Competitive Landscape & Market Share Analysis

4.7. Technology Advancement in Vaccine Contract Manufacturing Market

4.8. Key Trends in the Market

Chapter 5. Market Segmentation 1: Vaccine Type Estimates & Trend Analysis

5.1. Vaccine Type & Market Share, 2019 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2031 for the following Vaccine Type:

5.2.1. Avian Expression Systems

5.2.2. Bacterial Expression Systems

5.2.3. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)

5.2.4. Insect Expression Systems

5.2.5. Mammalian Expression Systems

5.2.6. Plant Expression Systems

5.2.7. Yeast Expression Systems

Chapter 6. Market Segmentation 2: Type of Expression System Estimates & Trend Analysis

6.1. Type of Expression System & Market Share, 2019 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2031 for the following Type of Expression System:

6.2.1. Attenuated

6.2.2. Inactivated

6.2.3. Subunit-based

6.2.4. Toxoid-based

6.2.5. DNA-based

Chapter 7. Market Segmentation 3: Workflow Estimates & Trend Analysis

7.1. Workflow & Market Share, 2019 & 2031

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2031 for the following Workflow:

7.2.1. Downstream

7.2.2. Upstream

Chapter 8. Market Segmentation 4: Application Estimates & Trend Analysis

8.1. Application & Market Share, 2019 & 2031

8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2031 for the following Application:

8.2.1. Human Use

8.2.2. Veterinary

Chapter 9. Vaccine Contract Manufacturing Market Segmentation 5: Regional Estimates & Trend Analysis

9.1. North America

9.1.1. North America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Vaccine Type, 2023-2031

9.1.2. North America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Type of Expression System, 2023-2031

9.1.3. North America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Workflow, 2023-2031

9.1.4. North America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2023-2031

9.1.5. North America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2023-2031

9.1.5.1. U.S.

9.1.5.2. Canada

9.2. Europe

9.2.1. Europe Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Vaccine Type, 2023-2031

9.2.2. Europe Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Type of Expression System, 2023-2031

9.2.3. Europe Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Workflow, 2023-2031

9.2.4. Europe Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2023-2031

9.2.5. Europe Vaccine Contract Manufacturing Market revenue (US$ Million) by country, 2023-2031

9.2.5.1. Germany

9.2.5.2. France

9.2.5.3. Italy

9.2.5.4. Spain

9.2.5.5. UK

9.2.5.6. Rest of Europe

9.3. Asia Pacific

9.3.1. Asia Pacific Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Vaccine Type, 2023-2031

9.3.2. Asia Pacific Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Type of Expression System, 2023-2031

9.3.3. Asia Pacific Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Workflow, 2023-2031

9.3.4. Asia Pacific Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2023-2031

9.3.5. Asia Pacific Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2023-2031

9.3.5.1. China

9.3.5.2. India

9.3.5.3. Japan

9.3.5.4. Australia

9.3.5.5. Rest of Asia Pacific

9.4. Latin America

9.4.1. Latin America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Vaccine Type, (US$ Million)

9.4.2. Latin America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Type of Expression System, 2023-2031

9.4.3. Latin America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Workflow, 2023-2031

9.4.4. Latin America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, (US$ Million)

9.4.5. Latin America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2023-2031

9.4.5.1. Brazil

9.4.5.2. Rest of Latin America

9.5. MEA

9.5.1. MEA Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Vaccine Type, (US$ Million) 2023-2031

9.5.2. MEA Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Type of Expression System, 2023-2031

9.5.3. MEA Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Workflow, 2023-2031

9.5.4. MEA Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2023-2031

9.5.5. MEA Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2023-2031

9.5.5.1. GCC Countries

9.5.5.2. South Africa

9.5.5.3. Rest of MEA

Chapter 10. Competitive Landscape

10.1. Major Mergers and Acquisitions/Strategic Alliances

10.2. Company Profiles

10.2.1. Lonza

10.2.2. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

10.2.3. Ajinomoto Althea, Inc.

10.2.4. Merck KgaA

10.2.5. Cytovance Biologics

10.2.6. Catalent, Inc.

10.2.7. IDT Biologika GmbH

10.2.8. Albany Molecular Research, Inc.

10.2.9. PRA Health Sciences

10.2.10. ICON plc.

10.2.11. Pharmaceutical Product Development, LLC

10.2.12. Cobra Bio

10.2.13. Paragon Bioservices, Inc.

10.2.14. Charles River Laboratories

10.2.15. Meridian Life Science (MLS)

10.2.16. Eurogentec

10.2.17. GreenPak Biotech

10.2.18. Hong Kong Institute of Biotechnology

10.2.19. WuXi Biologics

10.2.20. Bharat Biotech

10.2.21. Biological E

10.2.22. Other Prominent Player

Segmentation of Vaccine Contract Manufacturing Market-

Vaccine Contract Manufacturing Market By Vaccine Type

  • Attenuated
  • Inactivated
  • Subunit-based
  • Toxoid-based
  • DNA-based

Vaccine Contract Manufacturing Market Seg

Vaccine Contract Manufacturing Market By Type of Expression System

  • Avian Expression Systems
  • Bacterial Expression Systems
  • Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
  • Insect Expression Systems
  • Mammalian Expression Systems
  • Plant Expression Systems
  • Yeast Expression Systems

Vaccine Contract Manufacturing Market By Workflow

  • Downstream
  • Upstream

Vaccine Contract Manufacturing Market By Application

  • Human Use
  • Veterinary

Vaccine Contract Manufacturing Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Vaccine Contract Manufacturing Market Size?

Vaccine Contract Manufacturing Market is expected to grow at a 17.8% CAGR during the forecast period for 2024-2031.

Paragon Bioservices, Inc., Charles River Laboratories, Meridian Life Science (MLS), Eurogentec, GreenPak Biotech, Hong Kong Institute of Biotechnology

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach